Sep 24 2010
Argos Therapeutics today announced that results from its Arcelis™ immunotherapy Phase 2 study for the treatment of renal cell carcinoma (RCC) have been accepted for a poster presentation at the Ninth International Kidney Cancer Symposium on Oct. 1-2 in Chicago.
The study is an open-label Phase 2 trial that enrolled 25 patients with newly diagnosed metastatic clear cell RCC. Post-nephrectomy, subjects received sunitinib and then concomitant AGS-003. The first endpoint was to evaluate clinical activity as measured by objective tumor response, and the secondary endpoints included safety, clinical activity via estimates of progression free survival, overall survival and assessment of clinical benefit as measured by stable disease, partial response, and CR rates and measurement of immune response.